

## PATENTS

1. WO/2008/114020: Henderson R, Tate CG, Magnani F, Serrano-Vega MJ, Shibata Y, Warne AJ. MUTANT G-PROTEIN COUPLED RECEPTORS AND METHODS FOR SELECTING THEM (2008)
2. WO/2013/091883: Magnani F, Tzakos A. SELECTIVE LIGANDS FOR THE ANGIOTENSIN II RECEPTORS (2013)
3. WO/2018/014939: Mattevi A., Nenci S., Magnani F. MUTATED FORM OF NADPH OXIDASES (2018).

## PUBLICATIONS (\* corresponding author)

1. "Enzyme Engineering" volume, Methods in Molecular Biology series (Springer). **Magnani F**, Marabelli C, Paradisi F. (Eds.), vol. 2397, ISSN: 1064-3745, doi: 10.1007/978-1-0716-1826-4
2. Reis J., Massari M., Marchese S., Ceccon M., Aalbers F.S., Corana F., Valente S., Mai A., **Magnani F.**, Mattevi A. (2020). A closer look into NADPH oxidase inhibitors: Validation and insight into their mechanism of action. REDOX BIOLOGY, vol. 32, ISSN: 2213-2317, doi: 10.1016/j.redox.2020.101466
3. Vrettos E.I., Valverde I.E., Mascarin A., Pallier P.N., Cerofolini L., Fragai M., Parigi G., Hirmiz B., Bekas N., Grob N. M., Stylos E., Shaye H., Del Borgo M., Aguilar M.-I., **Magnani F.**, Syed N., Crook T., Waqif E., Ghazaly E., Cherezov V., Widdop R. E., Luchinat C., Michael-Titus A. T., Mindt T. L., Tzakos A. G. (2020). Single Peptide Backbone Surrogate Mutations to Regulate Angiotensin GPCR Subtype Selectivity. CHEMISTRY-A EUROPEAN JOURNAL, ISSN: 0947-6539, doi: 10.1002/chem.202000924
4. Chiabrando D, Scietti L, Prajica AG, Bertino F, Tolosano E, Magnani F\* (2020). Expression and purification of the heme exporter FLVCR1a. PROTEIN EXPRESSION AND PURIFICATION, vol. 172, ISSN: 1046-5928, doi: 10.1016/j.pep.2020.105637
5. **Magnani F\***, Mattevi A\*. Structure and mechanisms of ROS generation by NADPH oxidases. Curr Opin Struct Biol. 2019 Apr 30;59:91-97. Review.
6. Ceccon M, Millana Fananas E, Massari M, Mattevi A, **Magnani F\***. Engineering stability in NADPH oxidases: a common strategy for enzyme production. Mol Membr Biol. 2018 Oct 11:1-28.
7. Iacovino LG, **Magnani F**, Binda C. The structure of monoamine oxidases: past, present, and future. J Neural Transm (Vienna). 2018 Aug 24.
8. Forneris F, Canciani A, Ciossani G, Palamini M, Chiapparino A, Gabrieli P, Guarino SR, Campioni M, Nenci S & **Magnani F** (2017). (2017). Acta Cryst. A73, C1276. ISSN: 2053-2733, Hyderabad, India, 21-28 August 2017, doi: 10.1107/S2053273317082985 (Atti di convegno)
9. **Magnani F\***, Nenci S, Millana Fananas E, Ceccon M, Romero E, Fraaije M, Mattevi A\*. Crystal structures and atomic model of NADPH oxidase. PNAS. 2017 Jun
10. Piano V, Nenci S, **Magnani F**, Aliverti A, Mattevi A. Recombinant human dihydroxyacetonephosphate acyl-transferase characterization as an integral monotopic membrane protein. Biochem Biophys Res Commun. 2016 Dec 2;481(1-2):51-58.
11. **Magnani F**, Serrano-Vega MJ, Shibata Y, Abdul-Hussein S, Lebon G, Miller-Gallacher J, Singhal A, Strege A, Thomas JA & Tate CG. A mutagenesis and screening strategy to generate

optimally thermostabilized membrane proteins for structural studies. *Nat Prot.* 2016 Jul 28; 11: 1554–1571.

12. **Magnani F**, Pappas C, Crook, T, Magafa V, Cordopatis P, Ishiguro S, Ohta N, Selent J, Bosnyak S, Jones ES, Gerothanassis I, Tamura M, Widdop ER, Tzakos AG (2014). Sculpting GPCR peptide-ligand subtype selectivity: tackling cancer via a novel target. In: *Journal of Peptide Science*, vol. 20, p. S40- S41, 111 River St, Hoboken 07030-5774, NJ USA:WILEY-BLACKWELL, ISSN: 1075-2617 (Atti di convegno)
13. **Magnani F**, Pappas C, Magafa V, Cordopatis P, Ishiguro S, Ohta N, , Bonvin A, Bosnyak S, Jones ES, Gerothanassis IP, Tamura M, Widdop RE, Tzakos A. Electronic Sculpting of ligand-GPCR subtype selectivity: the case of angiotensin II. *ACS-Chem Biol.* 2014; 9(7):1420-5.
14. Laursen NS, **Magnani F**, Gottfredsen RH, Petersen SV, Andersen GR. Structure, function and control of complement C5 and its proteolytic fragments. *Curr Mol Med.* 2012; 12(8):1083-97.
15. Doré AS, Robertson N, Errey JC, Ng I, Hollenstein K, Tehan B, Hurrell E, Bennett K, Congreve M, **Magnani F**, Tate CG, Weir M, Marshall FH. Structure of the Adenosine A(2A) Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine. *Structure.* 2011;19(9): 1283-93.
16. Shibata Y, White JF, Serrano-Vega MJ, **Magnani F**, Aloia AL, Grishammer R and Tate CG. Thermostabilization of the neurotensin receptor NTS1. *J Mol Biol.* 2009; 390(2):262-77.
17. **Magnani F**, Shibata Y, Serrano-Vega MJ, Tate CG. Co-evolving stability and conformational homogeneity of the human adenosine A2a receptor. *PNAS* 2008; 105(31):10744-9.
18. Serrano-Vega MJ, **Magnani F**, Shibata Y, Tate CG. Conformational thermostabilization of the beta1-adrenergic receptor in a detergent- resistant form. *PNAS* 2008; 105(3): 877-82.
19. **Magnani F**, Tate CG, Wynne S, Williams C, Haase J. Partitioning of the serotonin transporter into lipid microdomains modulates transport of serotonin. *J Biol Chem.* 2004; 279(37):38770-8.
20. Tate CG, Haase J, Baker C, Boorsma M, **Magnani F**, Vallis Y, Williams DC. Comparison of seven different heterologous protein expression systems for the production of the serotonin transporter. *Biochim Biophys Acta.* 2003; 1610(1):141-53.
21. Haase J, Killian AM, **Magnani F**, Williams DC. Regulation of the serotonin transporter by interacting proteins. *Biochem Soc Trans.* 2001; 29(Pt 6): 722-8. Review.
22. Pozza M, Bettelli C, **Magnani F**, Mascia MT, Manzini E, Calza L. Is neuronal nitric oxide involved in adjuvant-induced joint inflammation? *Eur J Pharmacol.* 1998; 359(1):87-93.